Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · FY 2026

Pure Bioscience FY 2026 Results: Net Loss of $2.48M, Loss Widens

PURE Bioscience, Inc. is focused on commercializing its proprietary Silver Dihydrogen Citrate (SDC) technology for food safety, including PURE Hard Surface and PURE Control. The company faces significant financial challenges, including a history of losses and a going concern warning from its auditors, necessitating additional capital to maintain operations.

FY 2026 at a glance · $ million · annual
MetricFY 2026FY 2025
Revenue2.32.2
Gross profit1.31.3
Net income-2.5-2.4
EPS (diluted, $ a share)$-0.02$-0.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+5.3%
Gross margin57.2%
Operating margin-89.9%
Source

10-K filed with the SEC, OTC: PURE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pure Bioscience, Inc.: key numbers

Share price
$0.0600Close, Nov 16
Market cap
$8.41M
Shares outstanding
140.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Miscellaneous Chemical ProductsSIC 2890

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pure Bioscience, Inc.

All →
4:06 PM ET 8-K
Financial Results

Pure Bioscience Financial Results

PURE Bioscience reported financial results for the fiscal year ended July 31, 2026, with net product sales increasing 5% to $2.3 million. The company posted a net loss of $2.5 million, or $0.02 per share, as growth in its end-user network was offset by a challenging macro environment and disruptions in the food industry.

Term
FY2026

“We are up year-over-year despite being a challenging year, with the macro environment causing increased expenses and foodborne outbreaks severely disrupting the food industry. Although our growth didn’t meet expectations, our focus remains on reducing costs and converting more opportunities into revenue.”

Jeff Kitchell, Chief Executive Officer
4:15 PM ET 8-K
Capital Raise

Pure Bioscience Capital Raise of $555K

PURE Bioscience completed a private placement financing raising $555,000 through the issuance of 10,183,486 shares of common stock. The investment was made by board member Tom Y. Lee and his affiliates at a price of $0.0545 per share, with proceeds intended for research, development, and general working capital.

Value
$555K
Counterparty
Tom Y. Lee

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.